Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)

v3.24.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
May 31, 2024
May 31, 2023
May 31, 2024
May 31, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)        
Revenue $ 84,000 $ 77,707 $ 380,278 $ 195,467
Cost of goods sold 0 12,747 4,822 31,500
Gross profit 84,000 64,960 375,456 163,967
Operating expenses        
Research and development 573,089 1,640,648 1,393,359 3,166,315
General and administrative 1,253,830 825,177 2,532,163 2,417,561
Total operating expenses 1,826,919 2,465,825 3,925,522 5,583,876
Loss from operations (1,742,919) (2,400,865) (3,550,066) (5,419,909)
Other income (loss)        
Interest income 0 15,443 7,318 34,174
Unrealized gain (loss) on marketable securities (41,393) 1,856 (79,335) (77,775)
Total other income (loss) (41,393) 17,299 (72,017) (43,601)
Net loss (1,784,312) (2,383,566) (3,622,083) (5,463,510)
Less: Net loss attributable to non-controlling interest (2,619) (12,061) (11,528) (37,930)
Net loss attributable to Lexaria shareholders (1,781,693) (2,371,505) (3,610,555) (5,425,580)
Other comprehensive income        
Foreign currency translation adjustment (1,240) 0 (21,866) 0
Total comprehensive loss $ (1,782,933) $ (2,371,505) $ (3,632,421) $ (5,425,580)
Basic and diluted loss per share $ (0.13) $ (0.37) $ (0.32) $ (0.89)
Weighted average number of common shares outstanding        
- Basic and diluted 13,855,202 6,440,998 11,274,845 6,116,126